 WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 GLOBE NEWSWIRE -- Cogent Biosciences, Inc. Nasdaq: COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET 7:00 a.m. CT to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 64th American Society of Hematology ASH Annual Meeting. 